The NPPA's 30% trade margin cap on 137 oncology drugs, effective November 9, has drawn support from the pharma industry, while patient groups question its impact on affordability.
The NPPA's 30% trade margin cap on 137 oncology drugs, effective November 9, has drawn support from the pharma industry, while patient groups question its impact on affordability.
<iframe src="https://hindustansphere.com/embed/cluster/8603f067e3828ba47db4e147d7e92a5f1e511ac8" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Centre's cancer drug margin cap draws mixed response from industry, groups"></iframe>
